TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01796730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bambuterol
Description: Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bambuterol
Description: Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bambuterol
Description: Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04108572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infant feeding
Description: Verbally delivered pre-specified infant feeding message. The messages focus on appropriate milk feeding and establishing complementary feeding and solid food introduction in relation to timing and practical guidance around processes of feeding and provision of additional infant-feeding resources including information leaflet, a magnet, an infant bib and access to an informational website.
Study: NCT03538964

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: non toric intraocular lens
Description: cataract surgery with implantation of a non toric intraocular lens
Study: NCT04028440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous γδT cells
Description: Cells will be extracted by apheresis, followed by expanding and activating. The autologous γδT cells product will be adoptive transferred.
Study: NCT00433537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Study: NCT00792389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm humidified C02
Description: Insufflation of warmed humidified gas during laparoscopic cholecystectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cool dry C02
Description: Insufflation of cool dry gas during laparoscopic cholecystectomy
Study: NCT01364493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab+Capecitabine+Oxaliplatin
Description: Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.~Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.~Oxaliplatin 130mg/m2 d1; q3w, 6 cycles
Study: NCT02009774

Intervention type: PROCEDURE
Intervention: NBI Function
Study: NCT00732082

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG-3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG-3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG-3

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAG-3
Study: NCT03546283

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The patients with hypertensive intracerebral hemorrhage will be randomized into giving placebos, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cattle Encephalon Glycoside and Ignotin
Description: The patients with hypertensive intracerebral hemorrhage will be randomized into giving CEGI, the other treatments in this group follow the guidelines on the treatment of hypertensive intracerebral hemorrhage.
Study: NCT03387072

Intervention type: OTHER
Intervention: Non interventional study
Description: mental stress test and Blood (or salivary) sample

Intervention type: OTHER
Intervention: Non interventional study
Description: mental stress test and Blood (or salivary) sample
Study: NCT00593463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycloserine
Description: Cycloserine: 500, 675, 750 mg oral capsule may possibly be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Diltiazem: 30, 60, 120 mg oral capsule may possibly be

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin: 100, 200, 400 mg oral capsule may possibly be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isradipine
Description: Isradipine: 5, 10 mg oral capsule may possibly be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine
Description: Nifedipine: 5, 10, 20 mg oral capsule may possibly be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline: I.M. injection may possibly be given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: Verapamil: 30, 60, 120 mg oral capsule may possibly be given
Study: NCT01992991

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation of motor cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Transcranial direct current stimulation of motor cortex
Study: NCT00520429

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACCES - Adjusting to Chronic Conditions with Education and Support
Description: The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
Study: NCT05840796

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein drink
Description: The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: casein protein drink
Description: The calories oral nutrition supplements were 100 kcal, which included 8.4g of protein and phosphorous was excluded in two oral nutrition supplements formula.~Each participant had two packs of nutrition supplement per day for 4 months. The 24-h dietary record, blood pressure, plasma glucose, lipid profile, renal function (estimated glomerular filtration rate, eGFR), inflammatory factor levels were analyzed at the baseline and at the 4th month of the study.~The participants were followed up until the 7th month of the study.
Study: NCT04371133

Intervention type: DIAGNOSTIC_TEST
Intervention: Adropin (ng/L)
Description: Thawed samples were measured on a Molecular Devices SpectraMax i3 Multi-Mode, Microplate Reader (batch number: SER 35 370-1448, made in Austria) using enzyme linked immunosorbent assay (ELISA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Adropin (ng/L)
Description: Thawed samples were measured on a Molecular Devices SpectraMax i3 Multi-Mode, Microplate Reader (batch number: SER 35 370-1448, made in Austria) using enzyme linked immunosorbent assay (ELISA).
Study: NCT00039286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Study: NCT03531294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: intravitreal 2mg aflibercept injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: intravitreal 2mg aflibercept injection
Study: NCT01022463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine 5 mg BId for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atenolol
Description: 50 mg od for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: 50 mg od for 4 weeks
Study: NCT01269086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Preventive Visit
Description: Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
Study: NCT01010555

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B
Description: Commercially marketed, silicone hydrogel, spherical contact lens
Study: NCT04386837

Intervention type: OTHER
Intervention: Turkish Aphasia Rapid Test
Description: Same
Study: NCT00852982

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise
Description: Nordic walking, with walking poles, five hours per week during four months
Study: NCT01010555

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balafilcon A
Description: Commercially marketed, silicone hydrogel, spherical contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: Commercially marketed, silicone hydrogel, spherical contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: enfilcon A
Description: Commercially marketed, silicone hydrogel, spherical contact lens
Study: NCT00852982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Nordic walking, with walking poles, five hours per week during four months
Study: NCT01342263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCDM
Description: The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
Study: NCT04374630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Commercially available paclitaxel for IV administration will be obtained by clinical sites in US.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Each afuresertib 50 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 50 mg of afuresertib (free base).~Each afuresertib 75 mg tablet, intended for oral administration, contains afuresertib (hydrochloride salt) equivalent to 75 mg of afuresertib (free base)
Study: NCT03612960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Description: Very low nicotine content cigarettes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal nicotine content cigarettes
Description: Normal nicotine content cigarettes
Study: NCT02305225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Deprivation
Study: NCT02924363

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI with or without contrast dye
Description: MRI scans of the heart are performed before and after the MitraClip clinical procedure with an FDA cleared device with or without an FDA approved contrast dye.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood samples collected to calculate hematocrit for measurements of the CMR extracellular matrix.
Study: NCT03827707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Noise
Description: Noise applied via headphones during 60 min after meal ingestion

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Silence
Description: Headphones without sound applied during 60 min after meal ingestion
Study: NCT03983109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiFaith loss of resistance detect syringe
Description: An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiFaith loss of resistance detect syringe
Description: An EpiFaith syringe will be used to detect the loss of resistance and facilitate the needle localization.
Study: NCT04000724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging (Text+Step)
Description: Participants receive three culturally competent, theory-based pre-written messages per day sent on a predetermined schedule. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WebApp (App+Step)
Description: Participants receive access to a culturally competent password-protected web-based application with transgender-specific resources, support, and health information. Participants who still exhibit sexual risk and do not uptake and/or adhere to PrEP at the 3-month assessment may also receive eCoaching for up to 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information/No Step
Description: Participants in the Information/No Step intervention will receive access to a static website with information about trans health, HIV/STI information and local resources tailored for transgender persons.
Study: NCT00455455

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Optifree RepleniSH Multipurpose Disinfecting Solution
Description: lens care system

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ReNu Multiplus Multipurpose Solution
Description: lens care system
Study: NCT02214732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cognitive Therapy
Description: The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
Study: NCT02440711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy storing foot (ESF)
Description: A commercially-available energy storing prosthetic foot
Study: NCT01025895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acl reconstruction - double bundle technique
Study: NCT02440711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Energy storing foot (ESF)
Description: A commercially-available energy storing prosthetic foot

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified running specific foot (mRSF)
Description: A running specific prosthetic foot customized for both running and walking activities

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified running specific foot (mRSF)
Description: A running specific prosthetic foot customized for both running and walking activities
Study: NCT01275469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFT505 80mg
Description: Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
Study: NCT04560738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-CC-92480
Description: Oral
Study: NCT04519749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-310
Description: 4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-310
Description: 4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-310
Description: 4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-310
Description: 4D-310 is a novel adeno-associated virus (AAV) gene therapy comprised of two active components: the capsid (4D-C102) and the transgene cassette, which encodes a codon-optimized full length human GLA transgene driven by the CAG promoter. 4D-310 has been engineered so that it cannot replicate (replication incompetent).
Study: NCT05855785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: dual task exercise
Description: 8-week, 3 times a week, 60-minute group exercise sessions, which were comprised of moderate-to-high intensity exercise and simultaneous cognitive tasks

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: home exercise
Description: 60-minute light intensity home exercise, 4 times a week for 8 weeks
Study: NCT02493283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone single dose
Description: Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration), urine (0-24 h, 24-48 h, 48-72 h, 72-96 h, 96 -120 h) and feces (on treatment days 1-5)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapsone multiple dose
Description: Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) s.i.d. for 7 days and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration), urine (last treatment day 0-24 h) and feces (on treatment days 12-15)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: leucocytes
Description: sampling for leucocytes collection: study days -1, 1, 14 and 15

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: leucocytes
Description: sampling for leucocytes collection: study days -1, 1, 14 and 15

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Met-Hb
Description: sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Met-Hb
Description: sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12
Study: NCT01959568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vitrectomy and tamponade
Description: In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.~In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy and tamponade
Description: In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.~In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location.
Study: NCT01208727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: postconditioning
Description: Direct postconditioning (brief repeated cycle of 4 occlusion and desocclusion of the initially occluded culprit coronary artery) after primary direct stenting.